Taltz and Zantac drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Taltz (ixekizumab) and Zantac (ranitidine hydrochloride). Common drug interactions include mouth ulceration among females and injection site mass among males.

The phase IV clinical study analyzes what interactions people have when they take Taltz and Zantac. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Taltz?

Taltz has active ingredients of ixekizumab. eHealthMe is studying from 29,778 Taltz users. Check the latest studies of Taltz.

What is Zantac?

Zantac has active ingredients of ranitidine hydrochloride. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 434,161 Zantac users. Check the latest studies of Zantac.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

12 people who take Taltz and Zantac together, and have interactions are studied.

What are the common drug interactions of Taltz and Zantac, by gender? *:

female:

Mouth ulceration (mouth ulcers)
Psoriasis (immune-mediated disease that affects the skin)
Pustular psoriasis (raised bumps on the skin that are filled with pus)
Injection site pain
Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
Hypersensitivity
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
Pruritus (severe itching of the skin)
Pruritus generalised (generalized itching)

male:

Injection site mass
Abdominal discomfort
Arthralgia (joint pain)
Hypoaesthesia (reduced sense of touch or sensation)
Muscular weakness (muscle weakness)
Oropharyngeal pain
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
Sleep disorder
Viral upper respiratory tract infection

What are the common drug interactions of Taltz and Zantac, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
Pulmonary embolism (blockage of the main artery of the lung)
Hypersensitivity
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
Pruritus (severe itching of the skin)
Pruritus generalised (generalized itching)
Rash
Rash generalised (rash on most of body parts)
Skin disorder (skin disease)
Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)

50-59:

n/a

60+:

Irritable bowel syndrome
Mouth ulceration (mouth ulcers)
Psoriasis (immune-mediated disease that affects the skin)
Pustular psoriasis (raised bumps on the skin that are filled with pus)
Injection site pain
Arthralgia (joint pain)
Oropharyngeal pain
Sleep disorder
Viral upper respiratory tract infection

What are the existing conditions these people have? *

Psoriasis (immune-mediated disease that affects the skin): 8 people, 66.67%
Nail Psoriasis (a nail disease, nail bed separation, and discoloration): 2 people, 16.67%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 1 person, 8.33%
Mood Swings (an extreme or rapid change in mood): 1 person, 8.33%
High Blood Cholesterol: 1 person, 8.33%
Hiatal Hernia (hernia resulting from the protrusion of part of the stomach through the diaphragm): 1 person, 8.33%
Ankylosing Spondylitis (type of arthritis affecting the spine): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Taltz and Zantac?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously